Stemline Therapeutics (STML) PT Lowered to $14 at Wedbush
- Wall Street comes off record highs ahead of big tech earnings
- Tesla (TSLA) Gains on Q2 Beat, Analysts Mostly Positive but Others Cautious
- China's Meituan (MPNGF) Plunges 17.6% to Push Hang Seng Index to 8-Month Lows as Heavy Selling Continues
- Raytheon (RTX) Gains on Beat-and-Raise, CEO Says Next War Will Be Fought in Cyber Space and Then Outer Space
- Dollar eases slightly with Fed in focus
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten lowered the price target on Stemline Therapeutics (NASDAQ: STML) to $14.00 (from $17.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First National Financial Corp. (FN:CN) (FNLIF) PT Lowered to Cdn$51 at Scotiabank
- Komatsu Ltd (6301:JP) (KMTUY) PT Raised to JPY3,600 at Morgan Stanley
- Larsen & Toubro Ltd. (LT:IN) (LTOUF) PT Raised to INR1,954 at BofA Securities
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!